HRS/ACC/AHA Expert Consensus Statement on the Use of ICD Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials
Published: May 09, 2014
- The use of implantable cardioverter-defibrillator (ICD) therapy is a widely accepted and important treatment for patients with cardiovascular disease who are at risk for life-threatening ventricular arrhythmias.
- Situations still exist that aren’t addressed by existing guidelines, which are limited to those specific populations in the trials included in those guidelines.
- This joint consensus statement helps identify those patients who will receive optimal benefit from the timely use of ICD therapy.
Supporting Materials
Recommended Reading
- 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
- ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Abnormalities
- ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (PDF)